Artificial intelligence (AI) investing has been a major theme in the markets in 2023 and 2024, and will likely be a trend in ...

There hasn't been a more popular software stock than Palantir (PLTR -2.50%) in the market during 2024. The stock has risen ...

Investors looking for a growth stock may be tempted to buy this company, but they shouldn't ignore one key factor.

The company reported an 18.8% increase in insurance revenue, reaching AED 5.5 billion, compared to AED 4.7 billion in Q3 2023 ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 years the immunosuppressive drug has been on the market, it brought in ...